New drug cuts relapse risk by half in rare immune disorder trial

MedicalXpress | juin 04, 2026

Stanford Medicine researchers and their colleagues found that a new drug, obexelimab, significantly reduces the risk of relapse in patients with IgG4-related disease, a rare chronic immune condition often misdiagnosed as cancer.